| This week's sponsor is INC Research. | |  | |
Top Stories Thursday, November 3, 2016 Just a few months after Roche posted what it deemed a “promising safety and efficacy profile” from a long-term test of its experimental hemophilia med, the Swiss major is now said to have suffered a setback after a number of patients had blood clots. Thursday, November 3, 2016 Allergan took an R&D hit this quarter as it emerged from analysts that a Phase II test of dermatology med VTP-38543, acquired as part of a $640 million buyout deal of Vitae in September, has failed. Thursday, November 3, 2016 NBE Therapeutics has raised CHF 20 million from investors including PPF Group and Boehringer Ingelheim Venture Fund. The antibody-drug conjugate (ADC) specialist will use the Series B to move its lead candidate through a Phase I/II trial. Thursday, November 3, 2016 Canadian cancer biotech Oncolytics announced alongside its financials that its long-standing president and CEO, Brad Thompson, will be leaving the company “immediately.” Thursday, November 3, 2016 In its first quarter after the merger of Quintiles and IMS Health, the newly formed single company said it has kick-started a $1.5 billion repurchase of QuintilesIMS' outstanding common stock as it also forms new business units. Thursday, November 3, 2016 When Valeant bought Sprout and its controversial female libido drug Addyi, it agreed to a marketing blitz that would deliver royalties to Sprout's former shareholders. Valeant bungled the job, those former investors say. And they’re taking their gripes to court. | This week's sponsor is MedNet. | |  | Successfully Managing Registries with eClinical Technology
Free case study: See how eClinical technology supported a disease-specific Registry, ensuring the quick attainment of enrollment goals and the creation of multiple publications. Download now. |
| | | EnBiotix has completed the asset buyout of AMP Therapeutics, an antimicrobial peptide portfolio company from both Novartis and Boehringer’s venture arms. Release A new report by a former health minister in the U.K. says a ‘hard Brexit’ could delay new meds getting to patients. Story Acadia Pharmaceuticals has started a new Phase III test for its med pimavanserin as an adjunctive therapy for schizophrenia in patients who don’t respond well with current antipsychotics. Statement | |
|
Resources Presented By: Lenovo Get the stats you need to start down the path to a more secure infrastructure, today. Presented By: Lenovo What's the first step to a better patient experience? The patient experience starts well before the exam room or even reception - it begins as soon as your patients pull into the parking structure. Presented by: DocuSign DocuSign’s eSignature solutions modernize healthcare and life science organizations by eliminating paper and antiquated signature processes while meeting compliance requirements and reducing costs and errors. Presented by: DocuSign The patients who rely on your scientific leadership are expecting more. Presented by: DocuSign The U.S. Department of Justice has collected upwards of $17 billion in settlements from the healthcare industry since 2009, including more than $2 billion from a single life sciences company. Sponsored By: Salesforce Life sciences companies, like many industries today, face new challenges across the board. Read More. Presented By: ISR Reports Make essential outsourced bioprocessing decisions by staying informed of industry outsourcing practices and contract manufacturer usage patterns with ISR’s Bioprocessing Services and Technologies Market Trends and Outsourcing Dynamics report. Presented By: ISR Reports ISR’s Biosimilars in the US Oncology Market (2nd Edition) report provides data and insights from 101 US-based, board-certified oncologists/hematologist oncologists as to their expectations, fears, and aspirations for biosimilars in oncology. Presented By: ISR Reports Pinpoint the information oncologists find most valuable and the best sales channels for delivering specific types of data/information. Presented by: Covance The role of health economic data has never been more important. Presented by: Covance Leading manufacturers increasingly employ stakeholder research early in development to better identify the needs of patients and providers. Presented By: ISR Reports ISR’s Bioprocessing Market Trends and Outsourcing Dynamics: 2016-2021 report provides an overview of the current market dynamics for bioprocessing as well as an outlook on what the marketplace will look like in five years. Presented By: ISR Reports ISR’s CRO Quality Benchmarking – Phase II/III Service Providers (8th Edition) report provides a Consumer Reports-style analysis of Phase II/III CRO service quality from hundreds of users who rated 44 Phase II/III CROs across 26 critical dimensions of quality. Presented by: Patheon Can you avoid a risky trial-and-error approach to find the right path for your poorly soluble molecule by utilizing a CDMO? Download this complimentary Whitepaper to learn more! Presented by: Biotech Primer This 3-part webinar series is specifically geared toward the non-science professional who needs to better understand industry terminology, science, techniques and issues. Sponsored by: Veeva Systems Gartner research on short- and long-term strategies for IDMP compliance. | 
